vimarsana.com
  1. Home
  2. Live Updates
  3. Peginterferon Lambda - Breaking News

Page 6 - Peginterferon Lambda News Today : Breaking News, Live Updates & Top Stories | Vimarsana

Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.

Ospedale maggiore policlinicoPietro lamperticoDavid coryBristol myers squibbHepatology divisionEuropean medicines agencyDrug administrationEiger biopharmaceuticals incUniversity of milanEiger biopharmaceuticalsHepatitis delta virusPeginterferon lambdaLiver diseaseDurable virologic responseOrphan designationFast track

Eiger BioPharmaceuticals Announces First Patient Enrolled in LIMT-2: A Phase 3 Study of Peginterferon Lambda in Patients with Chronic Hepatitis Delta Virus (HDV) Infection

/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.

Ospedale maggiore policlinicoPietro lamperticoDavid coryBristol myers squibbHepatology divisionEuropean medicines agencyDrug administrationEiger biopharmaceuticals incUniversity of milanEiger biopharmaceuticalsHepatitis delta virusPeginterferon lambdaLiver diseaseDurable virologic responseOrphan designationFast track

Eiger receives DSMB advice to continue Phase III Covid-19 therapy trial

Eiger has received a recommendation from the DSMB to continue the Phase III TOGETHER clinical trial of Peginterferon Lambda without changes.

David coryBristol myers squibbEiger biopharmaceuticalsData safety monitoring boardPeginterferon lambda

Eiger BioPharmaceuticals Reports Third Quarter 2021 Financial Results and Provides Business Update

/PRNewswire/ Eiger BioPharmaceuticals, Inc. (Nasdaq:EIGR), a commercial-stage biopharmaceutical company focused on the development of innovative therapies.

Erik atkissonProgeroid laminopathiesDavid coryCompany annual report on formEiger biopharmaceuticals incCommittee for medicinal products human useProgram updatesEiger biopharmaceuticalsHepatitis delta virusPeginterferon lambdaRare metabolicProcessing deficient progeroidMedicinal productsHuman useTemporary use authorizationErik atkisson general counsel

Eiger BioPharmaceuticals to Ho - GuruFocus com

GuruFocus Article or News written by PRNewswire and the topic is about:

Ohad etzionOspedale maggiore policlinicoPietro lamperticoNorah terraultHepatology divisionDepartment of gastroenterologyFaculty of health sciencesPrnewswire eiger biopharmaceuticals incSoroka university medical centerBen gurion university of the negevEiger biopharmaceuticals incA migliavacca centerUniversity of milanKey opinion leaderHepatitis delta virusPeginterferon lambda

© 2025 Vimarsana

vimarsana © 2020. All Rights Reserved.